CJEU Dismisses Appeal in Teva-Cephalon Patent Settlement Case

Strategic Insights -

The Court of Justice of the European Union (CJEU) has dismissed the appeal in the Teva Pharmaceuticals Industries and Cephalon v European Commission (Case C-2/24 P) regarding a 2005 patent settlement concerning modafinil. This decision is the latest development in a series of CJEU cases concerning patent settlement agreements, also known as "pay-for-delay" agreements. The CJEU has further refined the criteria for assessing such settlements under Article 101 of the Treaty on the Functioning of the European Union (TFEU), particularly where they involve value transfers between originator and generic companies.

Key Takeaways:

  • The CJEU upheld the General Court's (GC) judgment from 2023, confirming the European Commission's (EC) decision to impose fines totaling €60.5 million on Teva and Cephalon for their patent settlement agreement.
  • The CJEU refined the criteria for assessing patent settlement agreements, emphasizing that value transfers between originator and generic companies should be carefully documented and capable of demonstrating their commercial rationale.
  • The CJEU stressed the importance of early competition law review during settlement planning to mitigate enforcement risk and strengthen the defensibility of legitimate business strategies.
  • The two-part test from Generics (UK) remains the basis for determining whether a patent settlement agreement constitutes a restriction of competition "by object".
  • The CJEU clarified that examining the explanations offered by the parties and considering whether alternative justifications are sufficient to displace the finding that the settlement restricted competition by object is legitimate.
  • The assessments of "object" and "effect" are alternative, not cumulative, under Article 101 TFEU.
  • The judgment provides guidance on when patent settlement agreements may be regarded as restrictions "by object" under Article 101 TFEU, confirming that mere existence of value transfers does not render a settlement problematic.
  • Any payment, license, or ancillary arrangement forming part of a settlement should be carefully documented and capable of demonstrating that the agreement facilitates, rather than delays, competition.

Statistics:

  • €60.5 million: Total fines imposed by the EC on Teva and Cephalon for their patent settlement agreement.
  • 2005: Year in which Teva and Cephalon reached a settlement to resolve patent litigation concerning modafinil.
  • 2011: Year in which Teva acquired Cephalon, making the two companies part of the same group.
  • 2012: Year in which Teva was granted a licence from Cephalon to enter the UK market under the settlement agreement.
  • 2020: Year in which the EC adopted a decision finding that the settlement restricted competition within the meaning of Article 101 TFEU.
  • 2023: Year in which the General Court dismissed the action in its entirety, upholding the EC's conclusion that the settlement agreement constituted a restriction of competition "by object".
  • 2025: Year in which the CJEU dismissed the appeal in its entirety.

Sources:

  • European Commission decision (AT.39686 - Cephalon)
  • General Court judgment (Case T-74/21)
  • Court of Justice of the European Union (Case C-2/24 P)